NeuroHealing Appoints David Gwynne, VP Business Development
Initial Focus on NH02D Program for the Treatment of Premature Ejaculation Newton, Massachusetts – February 2, 2009. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, today announced the appointment of David Gwynne, Ph.D. as vice president, business development, responsible for NeuroHealing’s NH02D program…
Details